Scientific Methods to Evaluate Potential Reduced-Risk Tobacco Products
A new study from the Life Sciences Research Office, Inc. (LSRO), Scientific Methods to Evaluate Potential Reduced-Risk Tobacco Products, outlines laboratory and clinical testing approaches for the assessment of tobacco products with the potential to reduce the risks of cigarette smoking for individuals who switch from cigarettes to these products. This report and the scientific evaluation approach outlined by LSRO will be of interest to a number of audiences including academic, government and industry researchers; tobacco control and public health organizations; agencies with regulatory oversight of tobacco products, such as the Federal Trade Commission; as well as individuals involved in the development of legislation providing regulatory authority over tobacco products to public health organizations, such as the Food and Drug Administration, and agency staff. The report will also be of interest to current smokers (and their friends and family) who are unable or unwilling to quit smoking but are interested in reducing their risks due to smoking. This report was produced under a contract between Philip Morris USA, Inc. (Philip Morris) and LSRO. Findings, conclusions, and recommendations were developed independently of Philip Morris and represent the views of LSRO. - Publishers website.
What people are saying - Write a review
We haven't found any reviews in the usual places.
13 other sections not shown
Accessed adducts animal associated atherosclerosis Available Benowitz Biological Effects Assessment biomarkers biomarkers of effect biomarkers of exposure carcinogens causal relationship cell Centers for Disease chemical chemistry chronic cigarette smoke clinical studies Committee Conference on Harmonisation Control and Prevention conventional cigarettes COPD Disease Control etal evaluation ex-smokers Fagerstrom Federal Trade Commission harm reduction Hatsukami Henningfield human increased individuals infer a causal inhalation Institute of Medicine International lung cancer mainstream smoke marketing Medical methods nicotine replacement nicotine replacement therapy Nicotine Tob Res particulate Ph.D Philip Morris USA policies population risk preclinical PRRTP PRRTP users Public Health pulmonary reduced risk relevant risk assessment risk reduction Sciences Research Office scientific smoke constituents smokeless tobacco smoking cessation sufficient to infer tobacco control tobacco harm reduction tobacco smoke toxicity Toxicol Toxicology U.S. Department U.S. Environmental Protection U.S. Food University weight of evidence World Health Organization